N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide

C22H27N5O6S — CID 169098098

IUPACN-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
SMILESCOc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cn3)CC2)cc1
InChIInChI=1S/C22H27N5O6S/c1-16(28)23-14-19-15-27(22(29)33-19)17-3-8-21(24-13-17)25-9-11-26(12-10-25)34(30,31)20-6-4-18(32-2)5-7-20/h3-8,13,19H,9-12,14-15H2,1-2H3,(H,23,28)/t19-/m0/s1
InChIKeySKHOYDUMKGWMJO-IBGZPJMESA-N
MW489.55 g/mol
LogP1.06
Rot. Bonds7

About N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide

N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide (PubChem CID 169098098) has the molecular formula C22H27N5O6S and a molecular weight of 489.55 g/mol. Its IUPAC name is N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide.

Molecular Properties

Compound NameN-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
PubChem CID169098098
Molecular FormulaC22H27N5O6S
Molecular Weight489.55 g/mol
Exact Mass489.17
IUPAC NameN-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
SMILESCOc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cn3)CC2)cc1
InChIInChI=1S/C22H27N5O6S/c1-16(28)23-14-19-15-27(22(29)33-19)17-3-8-21(24-13-17)25-9-11-26(12-10-25)34(30,31)20-6-4-18(32-2)5-7-20/h3-8,13,19H,9-12,14-15H2,1-2H3,(H,23,28)/t19-/m0/s1
InChIKeySKHOYDUMKGWMJO-IBGZPJMESA-N
XLogP1.06
TPSA121.38 Ų
H-Bond Donors1
H-Bond Acceptors8
Rotatable Bonds7
Heavy Atoms34
Complexity

Lipinski Rule of Five

Passes Rule of Five

RuleValue
MW ≤ 500489.55
LogP ≤ 51.06
H-Bond Donors ≤ 51
H-Bond Acceptors ≤ 108

Analyze N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide?
The IUPAC name of N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide (CID 169098098) is N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide.
What is the SMILES notation for N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide?
The canonical SMILES for N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide is COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cn3)CC2)cc1.
What is the InChIKey of N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide?
The InChIKey is SKHOYDUMKGWMJO-IBGZPJMESA-N. The full InChI is InChI=1S/C22H27N5O6S/c1-16(28)23-14-19-15-27(22(29)33-19)17-3-8-21(24-13-17)25-9-11-26(12-10-25)34(30,31)20-6-4-18(32-2)5-7-20/h3-8,13,19H,9-12,14-15H2,1-2H3,(H,23,28)/t19-/m0/s1.
What are the key properties of N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide?
N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide has a molecular weight of 489.55 g/mol, XLogP of 1.06, 7 rotatable bonds, 1 hydrogen bond donors, and 8 hydrogen bond acceptors.
Where does this data come from?
All data for N-[[(5S)-3-[6-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-3-pyridinyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide is sourced from PubChem (CID 169098098), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).